109 related articles for article (PubMed ID: 29448044)
1. Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2.
Hashimoto Y; Hata T; Tada M; Iida M; Watari A; Okada Y; Doi T; Kuniyasu H; Yagi K; Kondoh M
Eur J Pharm Sci; 2018 May; 117():161-167. PubMed ID: 29448044
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
[TBL] [Abstract][Full Text] [Related]
3. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
Li X; Iida M; Tada M; Watari A; Kawahigashi Y; Kimura Y; Yamashita T; Ishii-Watabe A; Uno T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):206-13. PubMed ID: 25118216
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
Hashimoto Y; Kawahigashi Y; Hata T; Li X; Watari A; Tada M; Ishii-Watabe A; Okada Y; Doi T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Pharmacol Res Perspect; 2016 Oct; 4(5):e00266. PubMed ID: 27713828
[TBL] [Abstract][Full Text] [Related]
5. Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.
Shimizu Y; Yoneda K; Shirasago Y; Suzuki T; Tada M; Ishii-Watabe A; Sugiyama K; Suzuki T; Wakita T; Yagi K; Kondoh M; Fukasawa M
Biochem Biophys Res Commun; 2019 Jun; 514(3):785-790. PubMed ID: 31079928
[TBL] [Abstract][Full Text] [Related]
6. Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.
Yang H; Park H; Lee YJ; Choi JY; Kim T; Rajasekaran N; Lee S; Song K; Hong S; Choi JS; Shim H; Kim YD; Hwang S; Choi YL; Shin YK
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31905631
[TBL] [Abstract][Full Text] [Related]
7. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
[TBL] [Abstract][Full Text] [Related]
8. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate.
Tachibana K; Hashimoto Y; Shirakura K; Okada Y; Hirayama R; Iwashita Y; Nishino I; Ago Y; Takeda H; Kuniyasu H; Kondoh M
J Control Release; 2021 Aug; 336():105-111. PubMed ID: 34118338
[TBL] [Abstract][Full Text] [Related]
10. Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian Model.
Hashimoto Y; Shirakura K; Okada Y; Takeda H; Endo K; Tamura M; Watari A; Sadamura Y; Sawasaki T; Doi T; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2017 Nov; 363(2):275-283. PubMed ID: 28819070
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
13. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
14. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.
Qing Y; Shuo W; Zhihua W; Huifen Z; Ping L; Lijiang L; Xiaorong Z; Liming C; Daiwen X; Yu H; Wei X; Min F; Zuohua F; Guanxin S
Cancer Immunol Immunother; 2006 Sep; 55(9):1111-21. PubMed ID: 16341531
[TBL] [Abstract][Full Text] [Related]
15. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
16. Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5.
Hashimoto Y; Zhou W; Hamauchi K; Shirakura K; Doi T; Yagi K; Sawasaki T; Okada Y; Kondoh M; Takeda H
Sci Rep; 2018 May; 8(1):8383. PubMed ID: 29849184
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
Cherradi S; Ayrolles-Torro A; Vezzo-Vié N; Gueguinou N; Denis V; Combes E; Boissière F; Busson M; Canterel-Thouennon L; Mollevi C; Pugnière M; Bibeau F; Ychou M; Martineau P; Gongora C; Del Rio M
J Exp Clin Cancer Res; 2017 Jun; 36(1):89. PubMed ID: 28659146
[TBL] [Abstract][Full Text] [Related]
18. CA215 and GnRH receptor as targets for cancer therapy.
Lee G; Cheung AP; Ge B; Zhu M; Giolma B; Li B; Wong E; Li Y; Wang Y; Chen Z; Gu J
Cancer Immunol Immunother; 2012 Oct; 61(10):1805-17. PubMed ID: 22430628
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
20. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
